Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: An extended phase II study

Annals of Tropical Paediatrics

Volumn 26, Issue 4, 2006, Pages 357-361

  Khalil, Eltahir Awad Gasim ^a   Musa, Ahmed Mudawi ^a   Modabber, Farroukh ^b   El Hassan, Ahmed Mohamed ^a  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b Infectious Diseases Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIUM ANTIBODY; BCG VACCINE; LEISHMANIA VACCINE; PLACEBO; ALUMINUM SULFATE; AUTOCLAVED LEISHMANIA MAJOR VACCINE; PROTOZOAL VACCINE; PROTOZOON ANTIBODY; VACCINE;

IMMUNE RESPONSE; LEISHMANIASIS; PARASITOLOGY; SAFETY; VACCINATION; VACCINE; YOUNG POPULATION;

ADOLESCENT; ANTIBODY TITER; ARTICLE; AUTOCLAVE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE ULCER; LYMPHADENOPATHY; NORMAL HUMAN; PRECIPITATION; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE DRUG DOSE; SKIN TEST; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; VOLUNTEER; ANIMAL; BIOSYNTHESIS; BLOOD; FEMALE; IMMUNOLOGY; LEISHMANIA MAJOR; MALE; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD;

LEISHMANIA MAJOR;

ADOLESCENT; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, PROTOZOAN; BCG VACCINE; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEISHMANIA MAJOR; LEISHMANIASIS, VISCERAL; MALE; PROTOZOAN VACCINES; SKIN TESTS; VACCINES, COMBINED;

EID: 34447321021     PISSN: 02724936     EISSN: None     Source Type: Journal    
DOI: 10.1179/146532806X152890     Document Type: Article

References (18)

1. De Beer P, Harith AE, Grootheest van M, Winkler A. Outbreak of kala-azar in Sudan. Lancet 1990; 335:224.
2. El Hassan AM, Hashim FA, Siddig, MA, Ghalib HW, Zijlstra EE. Kala-azar in Western Upper Nile in southern Sudan and its spread to a nomadic tribe from the north. Trans R Soc Trop Med Hyg 1993; 87:387-95.
3. Zijlstra EE, El-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 2001; 95 (suppl 1):S27-58.
4. Modabber F. Experience with vaccines against cutaneous leishmaniasis of men and mice. Parasitology 1989; 98:S49-60.
5. Sharifi I, FeKri AR, Aflatonian MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Barn, Iran. Lancet 1998; 351:1540-3.
6. Bahar K, Dowlati Y, Shidani B, et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 1996; 14:489-95.
7. Khalil EAG, Elhassan AM, Zijlstra EE, et al. Safety and immunogenicity of an autoclaved L. major vaccine. East Afr Med J 2000; 77:468-70.
8. Khalil EAG, El Hassan AM, Zijlstra EE, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356:1565-9.
9. Kamil AA, Khalil EAG, Musa AM, et al. Alum-precipitated autoclaved L. major plus BCG, a candidate vaccine for visceral leishmaniasis: safety, skin delayed hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003; 97:365-8.
10. Khalil EAG, Ayed NB, Musa AM, et al. Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 2005; 140:349-53.
11. Musa AM, Khalil EAG, Ismail A, et al. Safety, immunogenicity and possible efficacy of immunochemotherapy of persistent post kala-azar dermal leishmaniasis (PKDL). Sudan J Dermatol 2005; 3:63-72.
12. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and Alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999; 15:4481-8.
13. Misra A, Dube A, Srivastava B, et al. Successful vaccination against Leishmania donovani infection in Indian langur using Alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001; 14:3485-92.
14. Antunes CM, Mayrink W, Magalhaes PA, et al. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 1986; 15:572-80.
15. Momeni AZ, Jalayer T, Emamjomeh M, et al. A randomized, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17:466-72.
16. Hashemi-Fesharki R, Ale-Agha S, Habibi GR, et al. Production of inactivated wet rural Leishmania vaccine against L. major vaccine. Iran J Med Sci 1998; 3:74-80.
17. Sokal JE. Measurement of delayed skin test responses. N Engl J Med 1975; 293:501-2.
18. Harith AE, Kolk AHJ, Kager PA, et al. A simple and economical direct agglutination test for sero-diagnosis and sero-epidemiological studies of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1986; 80:583-7.